While technology is no silver bullet able to solve all that ails the healthcare industry, it has always been part and parcel of any revolution.
Think of the printing revolution and its influence of the Protestant Reformation that forever created a breach in the Catholic church.
Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, announces that C. Eric Winzer, M.B.A., currently serving Immunomic as Chief Financial Officer, will join the Board of Directors.
“Mr. Winzer’s keen financial expertise and broad industry experience will be a valuable addition to the Immunomic Board of Directors,” announced Immunomic CEO, Dr. William Hearl. “The Board has appreciated his prior contribution to our meetings and we are pleased to formally add him to this important advisory team.”
The Inova Health System have launched Inova Strategic Investments and the Inova Personalized Health Accelerator. Inova Strategic Investments will invest in healthcare venture funds as well as make direct investments in companies. IPHA will accept six to eight companies per year, providing education and funding. Hooks Johnston and Peter Jobse have been named managing directors of these new Inova vehicles.
Nearly half of the U.S. states and the District of Columbia saw a 10 percent or greater increase in higher education R&D expenditures from FY 2010 to FY 2015 with five of those states (Connecticut, Georgia, Massachusetts, Nebraska, and Utah) seeing at least a 20 percent change, according to the National Science Foundation’s (NSF) Higher Education Research and Development (HERD) survey for 2015. Between FY10-15 overall U.S. research and development (R&D) spending at U.S. universities grew 12.1 percent, from about $61.2 billion to $68.7 billion.
Gov. Andrew Cuomo proposed a new initiative this week to grow the life science research cluster throughout the state, pledging $550 million through a variety of programs including tax incentives, state capital grants, and investment capital with an expected match of $100 million from private sector partnerships for operating support.
Looking for the world’s best university startups! $1,500,000 in PRIZES 42 Startup Teams will be invited to compete in front of hundreds of investors, mentors, and partners to help launch their startups!
Competition Dates: April 6-8, 2017 – Rice University, Houston, Texas
Apply Now: Deadline: Friday, February 10, 2017
After a national search, Mike Psarouthakis has been selected as the new director of the U-M Tech Transfer Venture Center. The Venture Center is responsible for helping to identify, develop and launch new startups based on U-M technologies, and works alongside licensing, legal and marketing specialists within U-M Tech Transfer.
Genomenon Inc., a DNA interpretation software company launched from the University of Michigan in FY 2015, recently announced the completion of its extended seed financing of $1.8 million. The financing will fuel the completion and launch of Genomenon’s initial product, Mastermind, a novel analytic and visualization tool for DNA variant interpretation. Investors included two University of Michigan funds, as well as the Michigan Angel Fund and an angel group formed by Rehmann owners.
Nineteen. That’s the number of new drugs approved by the FDA thus far in 2016. With just over two weeks to go, there is little hope for a stellar year like 2015, which yielded 45 approvals.
What gives?
In their bid to host the 2024 Olympics, Washington business leaders plotted a transformation of the region into a more accessible, economically powerful and inclusive place, one that would glisten on the world athletic stage.
